WHAT IS CLAIMED IS:

1. A method for screening pharmaceuticals comprising detecting cross talk between intracellular signal from TGF-β family receptor and an intranuclear receptor.

2. A method for screening pharmaceuticals which induce cross talk between intracellular signal from TGF-β family receptor and an intranuclear receptor.

3. A method for screening pharmaceuticals which inhibit cross talk between intracellular signal from TGF-β family receptor and an intranuclear receptor.

4. A method for screening pharmaceuticals comprising detecting interaction between an intranuclear receptor and Smad molecule.

5. The method for screening pharmaceuticals as claimed in Claim 4, characterized in that said interaction with said Smad molecule is detected by using the Two-Hybrid System.

6. The method for screening pharmaceuticals as claimed in Claim 4, characterized in that said interaction with said Smad molecule is detected by using antigen-antibody reaction.

7. A method for screening of pharmaceuticals comprising detecting interaction between a transcription coupling factor and Smad molecule.

8. The method for screening pharmaceuticals as

claimed in Claim 7, characterized in that said

transcription coupling factor is CBP and/or p300.

9. A method for screening of pharmaceuticals

comprising detecting interaction among an intranuclear

5   receptor, Smad molecule and an transcription coupling

factor.

10. The method for screening pharmaceuticals as

described in Claim 9, characterized in that said

transcription coupling factor is CBP and/or p300.

10   11. The method for screening pharmaceuticals as

described in Claim 1, characterized in that said

intranuclear receptor is vitamin D receptor.

12. The method for screening of pharmaceuticals as

described in Claim 1, characterized in that said Smad

15   molecule is Smad3.

13. A method for molecular design for

pharmaceuticals characterized by using steric structural

data of the binding site of Smad molecule with an

intranuclear receptor and CPB and/or p300 as a

20   transcription coupling factor.